Literature DB >> 8157353

Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences.

A Scarpa1, P Capelli, A Villaneuva, G Zamboni, F Lluìs, R Accolla, G Mariuzzi, G Capellà.   

Abstract

Seventy-seven pancreatic adenocarcinomas (60 Spanish and 17 Italian) were tested for Ki-ras gene mutations by analysis of polymerase chain reaction amplified sequences. Mutations involving codon 12 (GGT; gly) were detected in 16 Italian and 46 Spanish cases (80.5% in total). All Italian mutations involved the second base and were G to A transitions (GAT; asp) in 8 cases and G to T transversions (GTT; val) in the remaining 8. Forty-two Spanish mutations were characterized. Thirty-eight were at the second and 4 at the first base: asp in 24 cancers, val in 14, arg (CGT) in 2 and cys (TGT) in 2. Previous European studies and our present data show that 149 of the 186 pancreatic cancers harbored a codon 12 Ki-ras mutation (80%), the large majority affecting the second base (73%), with a transitions/transversions ratio of 1.3:1. However, the mutational pattern of cancers of the different European countries shows remarkable differences, both in the site of the mutation (first or second base) and in the ratio of transitions over transversions. Moreover, a significant subgroup of pancreatic carcinomas do not harbor Ki-ras mutations. The classification of pancreatic cancers, according to the presence or absence, and type of Ki-ras mutation, may be of importance in epidemiological studies. A critical reappraisal of existing epidemiological data, through a retrospective genotypic study using paraffin-embedded cancer samples, may reveal significant correlations with specific genotoxic agents.

Entities:  

Mesh:

Year:  1994        PMID: 8157353     DOI: 10.1002/ijc.2910570206

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations.

Authors:  P Rieske; J Bartkowiak; A Szadowska; M Debiec-Rychter
Journal:  Mol Pathol       Date:  1999-04

Review 2.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

3.  Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas.

Authors:  M M Song; Y Nio; Y Sato; K Tamura; K Furuse
Journal:  Int J Pancreatol       Date:  1996-10

Review 4.  Intraductal papillary mucinous tumors of the pancreas. Verona University Pancreatic Team.

Authors:  C Bassi; C Procacci; G Zamboni; A Scarpa; G Cavallini; P Pederzoli
Journal:  Int J Pancreatol       Date:  2000-06

5.  Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q.

Authors:  P S Moore; G Zamboni; A Brighenti; D Lissandrini; D Antonello; P Capelli; G Rigaud; M Falconi; A Scarpa
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

Review 6.  Molecular biology of exocrine pancreatic cancer.

Authors:  J L Soto; V M Barbera; M Saceda; A Carrato
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

7.  K-ras gene mutation in gall bladder carcinomas and dysplasia.

Authors:  T Ajiki; T Fujimori; H Onoyama; M Yamamoto; S Kitazawa; S Maeda; Y Saitoh
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

8.  Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples.

Authors:  R Ward; N Hawkins; R O'Grady; C Sheehan; T O'Connor; H Impey; N Roberts; C Fuery; A Todd
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

9.  Absence of ras gene mutations in early gastric carcinomas.

Authors:  M E Craanen; P Blok; B Top; L Boerrigter; W Dekker; G J Offerhaus; G N Tytgat; S Rodenhuis
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

10.  Impact of Ethnicity on Somatic Mutation Rates of Pancreatic Adenocarcinoma.

Authors:  Nayra S Amaral; Vivian Resende; José Sebastião Dos Santos; Luiz Felipe Lima; Debora C Moraes; Eitan Friedman; Luiz DE Marco; Luciana Bastos-Rodrigues
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.